Artificial intelligence performs as well as experienced radiologists in detecting prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

UCLA researchers have developed a new artificial intelligence system to help radiologists improve their ability to diagnose prostate cancer. The system, called FocalNet, helps identify and predict the aggressiveness of the disease evaluating magnetic resonance imaging, or MRI, scans, and it does so with nearly the same level of accuracy as experienced radiologists.

In tests, FocalNet was 80.5% accurate in reading MRIs, while radiologists with at least 10 years of experience were 83.9% accurate.

The research is published online in IEEE Transactions on Medical Imaging. The paper was presented at the IEEE International Symposium on Biomedical Imaging in April 2019 and was selected as the runner up-for best paper.

The paper can be found here.

FocalNet is an artificial neural network that uses an algorithm that comprises more than a million trainable variables; it was developed by the UCLA researchers. The team trained the system by having it analyze MRI scans of 417 men with prostate cancer; scans were fed into the system so that it could learn to assess and classify tumors in a consistent way and have it compare the results to the actual pathology specimen. Researchers compared the artificial intelligence system’s results with readings by UCLA radiologists who had more than 10 years of experience.

The research suggests that an artificial intelligence system could save time and potentially provide diagnostic guidance to less-experienced radiologists.

The study’s senior authors are Kyung Sung, assistant professor of radiology at the David Geffen School of Medicine at UCLA; Steven Raman, a UCLA clinical professor of radiology and a member of the UCLA Jonsson Comprehensive Cancer Center; and Dieter Enzmann, chair of radiology at UCLA. The lead author is Ruiming Cao, a UCLA graduate student. Other authors are Amirhossein Bajgiran, Sohrab Mirak, Sepideh Shakeri and Xinran Zhong, all of UCLA.

The work was supported by funds from the Integrated Diagnostics Program, Department of Radiological Sciences & Pathology, David Geffen School of Medicine at UCLA.

Table of Contents

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login